Proteolysis Targeting Chimera (PROTAC) technology has transitioned from a theoretical breakthrough in chemical biology to a validated clinical reality. In…
Read More
Digital pathology’s next act: Mining old tissue to spare future animal studies
The landscape of preclinical research is undergoing a seismic shift, driven by the convergence of digital pathology, artificial intelligence, and…
Read More
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
The landscape of oncology is undergoing a seismic shift as pharmaceutical giants Merck & Co. and Moderna reach a pivotal…
Read More
2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
The American Association of Pharmaceutical Scientists (AAPS) has announced a significant evolution for its flagship 2026 PharmSci 360 conference, set…
Read More
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice
The global landscape of immunology has shifted significantly in the wake of the COVID-19 pandemic, leaving the vast majority of…
Read More
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
In a decisive move to address the burgeoning public health risks associated with the proliferation of synthetic, highly potent derivatives…
Read More
After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
Chemotherapy-Induced Peripheral Neuropathy (CIPN) has long stood as one of the most stubborn and debilitating side effects in oncology. Characterized…
Read More
Pharma commercial vendor selection still runs on word of mouth and a Harvard MBA student aims to change that with Rx Almanac.
For pharmaceutical companies navigating the high-stakes transition from clinical development to commercial launch, the landscape of service providers remains remarkably…
Read More
A plate of spaghetti: Talus Bio boasts 5,000-fold faster drug screening by skipping protein folding
The pharmaceutical industry has long been defined by the pursuit of the "druggable" genome—a subset of proteins whose stable, pocketed…
Read More
Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
New York City–based Definium Therapeutics has reached a pivotal inflection point in the rapidly evolving landscape of psychedelic medicine. Following…
Read More
